The objective of this contract is to utilize gold nanoparticles (GNP) to elicit broadly neutralizing antibodies (BNABS) against the fusion peptide (FP) of HIV-1 GP41 to develop a protective vaccine…
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93020C00014
- Awardee
-
Neovaxsyn Inc. UEI EHMTBALCKFE8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,999
Award facts
- Opportunity
-
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Solicitation · SBIRPHS20201 · Posted Jun 21, 2019
- A Nanovaccine for Eliciting Broadly Neutralizing Antibodies Against HIV-1 Award Notice · Posted Jun 16, 2020
- Contract value 100% obligated
- $299,999.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 7 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Ames, IA 50014, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $299,999 |
About this award
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases, valued at $299,999, was awarded to Neovaxsyn Inc. to develop a protective HIV vaccine utilizing gold nanoparticles to elicit broadly neutralizing antibodies against the fusion peptide of HIV-1 GP41. The contract was awarded under the Small Business Innovation Research Program Phase I solicitation, which sought proposals for research and development supporting NIH and CDC agency missions, including alternatives to cell culture materials and cancer immunotherapy manufacturing. Neovaxsyn will conduct the research at its facility in Ames, Iowa over a period of one year from June 2020 through August 2021 under a firm fixed price contract. The award was made through the SBIR program's total small business set-aside authority.
Description
The objective of this contract is to utilize gold nanoparticles (GNP) to elicit broadly neutralizing antibodies (BNABS) against the fusion peptide (FP) of HIV-1 GP41 to develop a protective vaccine against the virus.
Quick answers
Who was awarded contract 75N93020C00014?
75N93020C00014 was awarded to Neovaxsyn Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 1, 2020.
How much is contract 75N93020C00014 worth?
The government has obligated $299,999 on 75N93020C00014.
Was contract 75N93020C00014 competed?
The extent of competition for 75N93020C00014 was full and open competition after exclusion of sources. The government received 7 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award